Hemophilia B Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Hemophilia B remains an active clinical development field. One-time and precision therapies are raising the efficacy ceiling, but durability, manufacturing, small-population evidence and long-term safety remain decisive constraints. The PatSnap evidence set used here contains 94 matched trial records and 138 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| CTR20262597 | SR-604 | Phase 2; 进行中 （尚未招募） | Shanghai RAAS Blood Products Co., Ltd. | China | (首次用药至出组访视) | Timing not listed |
| NCT07682519 | Intervention not normalized | Not Applicable; Recruiting | University of Chile | Chile | Pain Intensity (Baseline and immediately after the 6-week intervention.) | 2027-01-15 |
| CTR20262400 | Human Coagulation Factor IX (Yuanda Shuyang) | Phase 3; 进行中 （尚未招募） | Grand Shuyang Life Sciences (Chengdu) Co., Ltd. | China | (6个月) | Timing not listed |
| NCT07644832 | SR-604 | Phase 1/2; Recruiting | Shanghai RAAS Blood Products Co., Ltd. | China | Part A: Incidence of AEs/SAEs/AESI (Part A: From Baseline (Day 1) up to Day 85); PartA: Incidence of drug-related AEs/SAEs/AESIs (Part A: From Baseline (Day 1) up to Day 85) | 2026-12-31 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B (Phase 3): the indexed record reports Adjusted annualized bleeding rate(months 7 through 60 after gene therapy) = 1.52 events per year.
- Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B (Phase 3): the indexed record reports Adjusted annualized bleeding rate(months 7 through 60 after gene therapy) = 1.52 events per year.
- Long term effect of marstacimab prophylaxis in hemophilia Α and Β on target joints: Results from BASIS and OLE studies (Phase 3): the indexed record reports Annualized bleeding rate(treated TJ bleeds) = 2.29 Event ( 5.52).
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including SR-604 (Phase 2; APC), Human Coagulation Factor IX (Yuanda Shuyang) (Approved; factor IX). Company & Deal Intelligence records identify sponsor context for Shanghai RAAS Blood Products Co., Ltd. (002252), University of Chile, Grand Shuyang Life Sciences (Chengdu) Co., Ltd.. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Natural-history-aligned endpoints that remain interpretable in small heterogeneous cohorts.
- Long-term registries for durability, immunogenicity and delayed safety signals.
- Redosing, rescue and treatment-sequencing strategies after incomplete response.
- Access models that address diagnosis, manufacturing and global delivery.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Hemophilia B has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
